[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:mbd5-wt-allele":3},{"name":4,"total":5,"recruiting":6,"trials":7},"MBD5 wt Allele",23,22,[8,16,22,29,35,41,47,53,59,66,72,77,83,89,95,101,107,113,119,125,131,137,143],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06993675","Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)",[12],"Phase 2","RECRUITING","2026-08-26T02:17:24.721169Z","2026-07-05T05:32:16.728555Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07400029","A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia",[12],"2026-08-26T02:17:17.791881Z","2026-07-05T05:32:16.679314Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT07200102","Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma",[26],"Phase 1","2026-08-26T02:18:25.327036Z","2026-07-05T05:32:16.663314Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07566364","Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD",[12],"2026-08-26T02:19:03.581490Z","2026-05-13T02:55:06.731598Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06511882","Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD",[12],"2026-08-26T02:15:02.712396Z","2026-05-05T02:43:29.703206Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT07053059","Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)",[12],"2026-08-26T02:18:19.586423Z","2026-05-05T02:43:29.369796Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT06429449","Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia",[26],"2026-08-26T02:17:39.048487Z","2026-05-05T02:43:28.971708Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT05344833","Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma",[12],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:28.676350Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":64,"content_modified":65},"NCT06284486","A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib",[63],"Phase 1\u002FPhase 2","2026-08-26T02:16:55.892527Z","2026-05-05T02:43:28.414692Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT07052695","Mosunetuzumab for CLL MRD Clearance",[63],"2026-08-26T02:15:57.572488Z","2026-05-05T02:43:28.401120Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":27,"content_modified":76},"NCT06910124","Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse",[12],"2026-05-05T02:43:28.296851Z",{"nct_id":78,"title":79,"phases":80,"status":13,"updated_at":81,"content_modified":82},"NCT06773208","A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)",[12],"2026-08-26T02:18:55.570428Z","2026-05-05T02:43:27.845089Z",{"nct_id":84,"title":85,"phases":86,"status":13,"updated_at":87,"content_modified":88},"NCT06107738","Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma",[12],"2026-08-26T02:17:07.954622Z","2026-05-05T02:43:27.414519Z",{"nct_id":90,"title":91,"phases":92,"status":13,"updated_at":93,"content_modified":94},"NCT05535855","UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1",[26],"2026-08-26T02:16:03.788292Z","2026-05-05T02:35:31.898196Z",{"nct_id":96,"title":97,"phases":98,"status":13,"updated_at":99,"content_modified":100},"NCT03509961","The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL",[12],"2026-08-26T02:19:19.975067Z","2026-05-05T02:35:31.695914Z",{"nct_id":102,"title":103,"phases":104,"status":13,"updated_at":105,"content_modified":106},"NCT07316010","Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma",[12],"2026-08-26T02:19:27.519777Z","2026-05-05T02:35:31.631978Z",{"nct_id":108,"title":109,"phases":110,"status":13,"updated_at":111,"content_modified":112},"NCT06483100","Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance",[12],"2026-08-26T02:17:39.857430Z","2026-04-29T02:57:57.142385Z",{"nct_id":114,"title":115,"phases":116,"status":13,"updated_at":117,"content_modified":118},"NCT06138587","Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation",[26],"2026-08-26T02:15:58.452248Z","2026-06-17T19:21:16.690731Z",{"nct_id":120,"title":121,"phases":122,"status":13,"updated_at":123,"content_modified":124},"NCT06500273","Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL",[12],"2026-08-26T02:17:19.710918Z","2026-05-05T02:43:28.207810Z",{"nct_id":126,"title":127,"phases":128,"status":13,"updated_at":129,"content_modified":130},"NCT07044544","Trial of Novel Anti-leukemia Agents in Flu\u002FMel RIC Transplant for Myeloid Malignancies",[26],"2026-08-26T02:15:21.365312Z","2026-05-05T02:43:27.317386Z",{"nct_id":132,"title":133,"phases":134,"status":13,"updated_at":135,"content_modified":136},"NCT06209619","CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma",[26],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:28.853554Z",{"nct_id":138,"title":139,"phases":140,"status":13,"updated_at":141,"content_modified":142},"NCT07645469","FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia",[26],"2026-08-26T02:17:38.215063Z","2026-06-14T18:39:22.265217Z",{"nct_id":144,"title":145,"phases":146,"status":147,"updated_at":148,"content_modified":149},"NCT02646839","KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL\u002FAML\u002FMDS Allo-HCT Children",[12],"ENROLLING_BY_INVITATION","2026-08-26T02:17:30.961790Z","2026-06-16T05:54:07.966507Z"]